LAWSUITS LINKING TYLENOL TO AUTISM REVIVED – U.S Court Revives more than 500 Hundred Of Private Lawsuits

A federal appeals court on Monday revived more than 500 private lawsuits against Tylenol maker Kenvue (KVUE.N), opening a new tab over ‌the painkiller’s alleged link to autism.

The 2nd U.S. Circuit Court of Appeals in Manhattan said a district court judge improperly excluded expert testimony from three doctors offered by parents and guardians who tied Tylenol use during pregnancy to autism and attention deficit hyperactivity disorder (ADHD) in children.

There is no firm scientific ​evidence of such a link. The issue drew greater attention after President Donald Trump and top U.S. health officials in ​September suggested a link to autism.

In a 64-page decision for a three-judge panel, Circuit Judge Guido Calabresi ⁠said the testimony from the three doctors, including the dean of Harvard University’s School of Public Health, reflected methodologies used by ​other scientists, and “constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree.”

The private lawsuits were dismissed in December 2024 by the U.S. ​District Judge Denise Cote in Manhattan, who criticized the methodology of the plaintiffs’ expert witnesses. Monday’s decision returns the lawsuits to Cote for further proceedings.